Product image of Paliperidone Ratiopharm (Paliperidone Palmitate) supplied by GNH India

Paliperidone Ratiopharm

Active Ingredient:
Paliperidone Palmitate
Origin:
EU

Paliperidone Ratiopharm (Paliperidone Palmitate)

Paliperidone Palmitate, the active ingredient in Paliperidone Ratiopharm, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It treats schizophrenia and schizoaffective disorder in adults and adolescents when oral therapy is insufficient or adherence is a concern.

GNH India supplies Paliperidone Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ratiopharm Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Paliperidone Ratiopharm is an atypical antipsychotic indicated for disorders that involve dopaminergic and serotonergic dysregulation.

  • Schizophrenia: reduces the frequency and severity of psychotic episodes and supports long‑term symptom control.
  • Schizoaffective disorder: alleviates both mood and psychotic symptoms, helping maintain functional stability.
  • Maintenance therapy for patients who have responded to oral paliperidone but need a long‑acting formulation to improve adherence.

How It Works

  • Paliperidone palmitate is a pro‑drug that slowly releases paliperidone after intramuscular injection. The active moiety antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in mesolimbic and mesocortical pathways, which reduces psychotic symptoms and stabilises mood.

Side Effects

Adverse reactions to paliperidone palmitate vary in frequency and severity.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the administration site.
  • Weight gain: gradual increase in body mass index.
  • Headache: transient cranial discomfort.
  • Restlessness (akathisia): inner sense of motor restlessness.
  • Fatigue: generalised tiredness.
  • Nasal congestion: mild upper‑respiratory irritation.

Serious or Rare Side Effects

  • Neuroleptic malignant syndrome: life‑threatening reaction with fever, rigidity and autonomic instability.
  • Tardive dyskinesia: persistent involuntary movements, often of the face.
  • Seizures: especially in patients with pre‑existing seizure disorders.
  • Hyperglycaemia: significant rise in blood glucose levels.
  • Orthostatic hypotension: marked drop in blood pressure upon standing.
  • Severe allergic reaction: anaphylaxis or angio‑edema requiring immediate medical attention.

Precautions & Warnings

When prescribing paliperidone palmitate, clinicians should consider several safety aspects.

  • Cardiovascular assessment: evaluate for QT‑interval prolongation and existing heart disease.
  • Metabolic monitoring: regularly check weight, glucose and lipid profiles.
  • Movement disorders: watch for early signs of akathisia or tardive dyskinesia.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Renal function: adjust expectations in patients with severe impairment.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Paliperidone palmitate may interact with other medicines, requiring vigilance.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure.
  • CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.
  • Antihistamines with anticholinergic properties: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration in plasma levels.

  • Drugs that prolong QT interval (e.g., certain antiarrhythmics, fluoroquinolones): monitor cardiac rhythm.
  • Lithium: may increase risk of neuro‑leptic malignant syndrome.
  • Antihypertensives: possible additive blood‑pressure lowering effect.

Frequently Asked Questions

Paliperidone Ratiopharm is a long‑acting injectable antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder in adults and adolescents, particularly when oral therapy is insufficient or adherence to daily medication is challenging.

Paliperidone palmitate is a pro‑drug that releases paliperidone, which blocks dopamine D2 and serotonin 5‑HT2A receptors. This antagonism reduces dopaminergic over‑activity and serotonergic imbalance in key brain pathways, helping to control psychotic symptoms and stabilise mood.

The dose of Paliperidone Ratiopharm is individualized by the prescribing clinician based on the patient’s clinical response, prior oral paliperidone exposure, and tolerability. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Paliperidone Ratiopharm should be used in pregnancy or while breastfeeding only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians usually consider alternative treatments and closely monitor maternal and fetal health.

To request Paliperidone Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Paliperidone Ratiopharm offers a once‑monthly injectable formulation of paliperidone, providing consistent plasma levels without daily oral dosing. Compared with other depot antipsychotics such as risperidone microspheres or aripiprazole lauroxil, it has a similar efficacy profile but differs in dosing interval, injection site tolerability and specific metabolic side‑effect risks.

Paliperidone Ratiopharm should be stored at room temperature, below 25 °C, in its original packaging. The product must be protected from moisture, excessive heat and direct sunlight to maintain stability.

Paliperidone Ratiopharm is given as an intramuscular injection, typically into the deltoid or gluteal muscle. A healthcare professional prepares the suspension and administers the dose according to the prescribed schedule, usually once every four weeks after an initial loading phase.

The most serious risks include neuroleptic malignant syndrome, tardive dyskinesia, seizures, severe hyperglycaemia, orthostatic hypot‑2

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Paliperidone Palmitate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT